rafaelnlins / Shutterstock.com

13 September 2024NewsBiotechnologySarah Speight

Sanofi signs global rights deal to develop rare cancer therapy

Sanofi will be responsible for global commercialisation of the medicine, used to treat neuroendocrine tumours | Pharma giant will pay up to $320m plus royalties to two biotech companies.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Sanofi subsidiary sues Sarepta over gene therapy

30 July 2024 Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.

Unified Patent Court: The cases, the numbers and what the future holds

27 June 2024 In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.

More on this story

Sanofi subsidiary sues Sarepta over gene therapy

30 July 2024 Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.

Unified Patent Court: The cases, the numbers and what the future holds

27 June 2024 In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.

More on this story

Sanofi subsidiary sues Sarepta over gene therapy

30 July 2024 Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.

Unified Patent Court: The cases, the numbers and what the future holds

27 June 2024 In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.

More features

The rise of pro-NPE and patent sentiment in the US

UPC sees rising small molecule litigation with Pfizer in the hot seat

Why the Caribbean cannabis economy is ripe for IP protection

China filings push rise in patent applications in Ireland

Brain disorder medtech rivals butt heads at ITC

The right formula: Minimising the cost of chemical and pharma patents

‘This is not a rescue deal’: How an acquisition fits London firm's plan

Alston & Bird partner with strong Japanese ties jumps to new firm